Phase 3 Bladder Cancer Trial, Recruiting NCT06537154 Sponsor: Peter Black Condition: Bladder Cancer
Back to Bladder Cancer

Phase 3 Bladder Cancer Trial, Recruiting

NCT06537154
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older.
  • You have been diagnosed with bladder cancer that is mainly a type called urothelial carcinoma, and it has grown into the muscle wall of the bladder (confirmed by a tissue sample).
  • Your cancer is at a stage where it has not spread to distant lymph nodes or other parts of the body (specific staging confirmed by imaging, and any enlarged lymph nodes must have been tested and shown to be cancer-free).
  • You have little to no additional flat, non-invasive cancer spots in your bladder — having just one such spot is acceptable.
  • You are in reasonably good general health and able to carry out daily activities (your doctor will assess this).
  • You are able to have a pelvic MRI scan.
  • Your doctors have determined you are a suitable candidate for either surgical removal of the bladder or a combined chemotherapy and radiation treatment.
  • You are able to receive standard pre-surgery chemotherapy (such as certain cisplatin-based drug combinations), or other standard treatments if guidelines have been updated since the trial was designed.
  • Your bladder works well enough, and you do not have a significant narrowing of the urethra, to allow for internal camera examinations of the bladder.

Who may not be able to join:

  • Your bladder cancer includes certain specific subtypes (small cell or plasmacytoid) in any part of the tumour.
  • You have previously received chemotherapy, immunotherapy, or certain targeted drug treatments for bladder cancer, or received such treatments for another cancer within the last 2 years.
  • There is no stored bladder tumour tissue available from a previous procedure (TURBT) that can be used for genetic testing.
  • You have had or currently have another type of cancer, unless it is a low-risk non-melanoma skin cancer, a very low-risk cancer not needing treatment (such as certain early prostate or breast conditions under monitoring), or you have been completely free of the other cancer for 5 or more years (some exceptions may be reviewed by the lead doctor).
  • You have previously had radiation therapy to the bladder area.
  • You have taken part in another experimental treatment study within the last 4 weeks.
  • You have an uncontrolled serious health condition, such as an active infection currently being treated with antibiotics, significant heart failure, unstable chest pain, an uncontrolled heart rhythm problem, or a mental health or personal situation that would make it difficult to follow the study requirements.
  • You are pregnant. If you could become pregnant, you must have a negative blood pregnancy test before any anaesthesia or MRI procedures.
  • You are currently enrolled in another clinical trial involving an active treatment (trials focused on quality of life or supportive care are generally acceptable).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Peter Black, MD, University of British Columbia

Phone: 604-875-5003

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Peter Black
Registry
ClinicalTrials.gov
Start date
28 July 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Proportion of patients found to have a cCR and randomized on the number of patients enrolled (pilot-RCT ; phase 2); Metastasis free survival at 2 years (phase 3)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov